TABLE 1

Demographics, disease severity, clinical, radiological, functional and microbiological characteristics of the study population

VariablesStudy population (n=401)
Demographics
 Female sex317 (79.1%)
 Age, years63 (50–71)
 Body mass index, kg·m−221.5 (19.5–24.0)
 Underweight58 (14.6%)
 Former or current smoker180 (44.9%)
Comorbidities
 GORD180 (44.9%)
 Rhinosinusitis138 (34.4%)
 Cardiovascular diseases142 (35.4%)
 Systemic hypertension93 (23.2%)
 Asthma60 (15.0%)
 Osteoporosis69 (17.2%)
 COPD32 (8.0%)
 Depression34 (8.5%)
 Anxiety27 (6.7%)
 History of neoplastic disease56 (14.0%)
 Diabetes17 (4.2%)
 BACI score0 (0–3)
Functional evaluation
 FEV1, % pred87 (71–101)
 FEV1 <50% pred30 (7.9)
 FVC, % pred, mean±sd97.5±21.7
Microbiology
 Chronic infection120 (35.9%)
 Chronic Pseudomonas aeruginosa infection76 (22.7%)
 Chronic Haemophilus influenzae infection20 (6.0%)
 NTM-PD41 (12.2%)
Clinical status
 Exacerbations2 (1–3)
 ≥3 exacerbations in the previous year132 (32.9%)
 LTOT19 (4.7%)
 Daily sputum267 (66.6%)
 Sputum volume, mL6 (4–20)
Chronic treatment
 Chronic macrolide therapy40 (10.0%)
 Chronic antibiotic inhaled therapy21 (5.2%)
Radiology
 Reiff score4 (2–6)
 Number of lobes involved3 (2–5)
Disease severity
 BSI score6 (3–9)
 BSI moderate–severe244 (63.9%)
 BSI severe98 (25.7%)
 FACED score2 (1–3)
 FACED moderate–severe141 (36.0%)

Data are presented as median (interquartile range) unless otherwise stated. GORD: gastro-oesophageal reflux disease; COPD: chronic obstructive pulmonary disease; BACI: before, after, control, impact; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; NTM-PD: nontuberculous mycobacterial pulmonary disease; LTOT: long-term oxygen therapy; BSI: bronchiectasis severity index; FACED: FEV1, age, chronic colonisation, extension, dyspnoea.